Prime Medicine reports Q1 EPS (28c), consensus (25c)

Reports Q1 revenue $856,000, consensus $844,220. “Prime Medicine (PRME) continues to execute with clear momentum and a focused strategy designed to deliver on the transformative potential of Prime Editing,” said Allan Reine, Chief Executive Officer of Prime Medicine. “We remain on track to file regulatory applications for PM577 in Wilson Disease in the first half of this year, and for PM647 in AATD mid-year, bringing two of our most advanced programs to the brink of clinical entry, with initial data from both expected in 2027. In parallel, we continue to progress toward a potential BLA filing for PM359, which, if successful, would bring a one-time, potentially curative therapy to people living with CGD, who today face a lifetime of debilitating infections and limited treatment options. With a strengthened leadership team and a continued commitment to disciplined capital allocation, we believe Prime Medicine is well positioned to execute across our pipeline and unlock the broad promise of Prime Editing for patients.”